“Since our founding in 2017, Herophilus’s vision has been to leverage the parallel revolutions in human complex in vitro brain models, scaled l...
The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a fou...
As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the prelimina...
—Creates leading global musculoskeletal company——Robust portfolio well-positioned for long-term growth and continued innovation— &...
“Ono has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opd...
Adding Four New Independent Directors Appoints John Greisch as Executive Chair Establishes New Strategic and Operational Review Committee of the Board ...
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to...
STARLIMS, a leading provider of enterprise informatics solutions, announces the expansion of its solution suite through the strategic acquisition of Labste...
The deal represents a total transaction value of up to $36 million with (i) an initial upfront consideration of $14 million, and (ii) up to an additional $...
Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire Pheno...
TAE Life Sciences has announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino aci...
– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix’s Tentacles™ Platform – – Gilead Re...
ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ is presently i...
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in d...
© 2025 Biopharma Boardroom. All Rights Reserved.
